| Quarterly Financials | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 58 | 34 | 30 | 20 | 21 | 18 | 13 | 15 | 27 | 19 | 8 |
| Expenses | 137 | 126 | 113 | 117 | 122 | 110 | 116 | 89 | 80 | 62 | 74 |
| EBITDA | -79 | -92 | -83 | -96 | -101 | -92 | -103 | -74 | -53 | -43 | -66 |
| Operating Profit % | -188 % | -427 % | -432 % | -740 % | -639 % | -555 % | -800 % | -494 % | -196 % | -540 % | -836 % |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 | 5 | 6 | 8 |
| Profit Before Tax | -82 | -95 | -86 | -100 | -105 | -96 | -107 | -79 | -61 | -52 | -76 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 |
| Net Profit | -82 | -95 | -86 | -100 | -106 | -96 | -107 | -80 | -60 | -52 | -76 |
| EPS in ₹ | -2.55 | -2.94 | -2.66 | -3.07 | -3.26 | -2.96 | -3.31 | -2.45 | -1.84 | -1.60 | -2.34 |
Sun Pharma Advanced Research Co
Sun Pharma Advanced Research Co
138.06
+7.34
(5.62%)
There are new updates from the company13 hours ago
Show All
Key Fundamentals
Market Cap
4,480.04 Cr
EPS
-10.55
PE Ratio
-15.89
Dividend Yield
0.00 %
Industry
Healthcare 52 Week High
241.00
52 Week Low
109.30
PB Ratio
-12.32
Debt to Equity
0.00
Sector
Pharmaceuticals Analyst Rating and Forecast
- By Refinitiv from1 analysts
Actual
Company News
View All News
Sun Pharma Advanced Research Company Ltd. announced that Ocuvex Therapeutics Inc. has resubmitted a Complete Response Letter to the US FDA for PDP-716 New Drug Application, addressing facility inspection-related conditions at a third-party API manufacturing facility from July 2023. The FDA had not raised any concerns related to the efficacy or safety of PDP-716, a novel once-daily ophthalmic suspension of brimonidine tartrate 0.35% developed using SPARC's proprietary TearAct technology.
Sun Pharma Advanced Research Company announced consolidation of its R&D laboratories from multiple sites in Mumbai and Baroda to two sites in Baroda, integrating operations from Mahakali and Makarpura sites into Savli and Tandalja locations. The strategic initiative aims to streamline R&D operations, enhance operational efficiencies, reduce cycle times, and accelerate proof-of-concept development, with some activities to be outsourced and excess capacity streamlined by end of FY26.
Sun Pharma Advanced Research Company Limited reported a net loss of ₹76 crores for the second quarter ended September 30, 2025, compared to ₹62 crores in the previous quarter. The half-year loss increased to ₹128 crores from ₹204 crores in the same period last year. Revenue from operations declined to ₹7.9 crores in Q2 from ₹9.6 crores in Q1. Total expenses for the quarter were ₹84 crores, with employee benefits expense at ₹26 crores and clinical trial expenses at ₹8 crores. The company's loss per share stood at ₹2.34 for the quarter. The company continues to incur cash losses and maintains going concern status based on support from its promoter group entity. The company operates solely in pharmaceutical research and development segment.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,777.40 | #1 4,26,457.80 | 40.83 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 71.49 | |
6,462.50 | 1,71,559.07 | 68.94 | 9,712.00 | 18.67 | 2,191 | 35.10 | 47.34 | |
3,721.40 | 1,25,949.09 | 58.99 | 11,539.40 | 6.99 | 1,911 | 30.46 | 54.89 | |
1,529.20 | 1,23,521.75 | 22.69 | 28,409.50 | 7.12 | 5,291 | 3.71 | 48.01 | |
1,248.60 | 1,04,209.87 | #1 18.19 | 33,741.20 | 16.73 | 5,725 | -0.38 | 53.56 | |
928.00 | 93,378.51 | 18.62 | 23,511.00 | 18.55 | 4,615 | 34.60 | 33.23 | |
2,030.80 | 92,757.71 | 21.28 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 58.77 | |
2,239.50 | 92,437.26 | 51.73 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 32.96 | |
1,207.70 | 70,143.41 | 21.12 | 32,345.60 | 9.43 | 3,484 | 3.81 | 63.26 | |
5,700.00 | 68,152.05 | 28.44 | 13,458.30 | 3.70 | 2,216 | 10.98 | 60.35 |
Growth Rate
Revenue Growth
-29.90 %
Net Income Growth
-11.54 %
Cash Flow Change
16.05 %
ROE
-151.27 %
ROCE
-659.67 %
EBITDA Margin (Avg.)
23.12 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2023 | 2024 | 2025 |
| Total Assets | 830 | 515 | 336 |
| Fixed Assets | 106 | 108 | 99 |
| Current Assets | 455 | 269 | 26 |
| Capital Work in Progress | 27 | 44 | 54 |
| Investments | 291 | 2 | 0 |
| Other Assets | 407 | 362 | 183 |
| Total Liabilities | 830 | 515 | 336 |
| Current Liabilities | 179 | 265 | 374 |
| Non Current Liabilities | 138 | 124 | 178 |
| Total Equity | 513 | 126 | -217 |
| Reserve & Surplus | 480 | 93 | -249 |
| Share Capital | 33 | 33 | 33 |
Cash Flow
| Cash Flow | 2023 | 2024 | 2025 |
| Net Cash Flow | -1 | 5 | -3 |
| Investing Activities | -548 | 392 | 158 |
| Operating Activities | -69 | -429 | -360 |
| Financing Activities | 617 | 42 | 199 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 68.46 % | 68.46 % | 68.10 % | 68.10 % | 69.09 % | 69.09 % | 69.09 % | 68.22 % | 65.67 % | 65.67 % | 65.67 % | 65.67 % | 65.67 % | 65.67 % | 65.67 % | 65.67 % | 65.67 % | 65.67 % | 65.67 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 3.30 % | 3.23 % | 2.64 % | 2.15 % | 2.23 % | 1.45 % | 1.47 % | 1.76 % |
| DIIs | 0.01 % | 0.02 % | 0.02 % | 0.02 % | 0.24 % | 0.24 % | 0.24 % | 0.93 % | 0.78 % | 0.78 % | 0.23 % | 0.81 % | 0.82 % | 0.18 % | 0.23 % | 0.64 % | 1.13 % | 0.97 % | 1.05 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 18.08 % | 18.00 % | 16.91 % | 16.94 % | 14.73 % | 16.45 % | 15.70 % | 16.00 % | 16.18 % | 16.13 % | 15.90 % | 16.09 % | 16.11 % | 18.91 % | 19.20 % | 18.89 % | 18.99 % | 19.15 % | 18.94 % |
| Others | 13.45 % | 13.52 % | 14.97 % | 14.94 % | 15.94 % | 14.22 % | 14.97 % | 14.85 % | 17.37 % | 17.42 % | 18.20 % | 14.13 % | 14.17 % | 12.60 % | 12.75 % | 12.58 % | 12.76 % | 12.73 % | 12.59 % |
| No of Share Holders | 0 | 99,454 | 1,10,301 | 94,834 | 95,039 | 93,097 | 94,494 | 93,718 | 96,337 | 1,00,807 | 1,01,433 | 1,03,990 | 1,02,743 | 1,25,184 | 1,28,205 | 1,31,034 | 1,42,864 | 1,40,724 | 1,36,997 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 17 Mar 2016 |  Rights | 5:116 | 16 Mar 2016 | 0.00 | 0.00 |
| 12 Aug 2024 |  Annual General Meeting | NA | 12 Aug 2024 | 251.25 | 218.80 |
| 04 Nov 2024 |  Quarterly Result Announcement | NA | 04 Nov 2024 | 207.65 | 216.10 |
| 10 Feb 2025 | Quarterly Result Announcement | NA | 10 Feb 2025 | 157.60 | 158.85 |
| 19 May 2025 | Quarterly Result Announcement | NA | 19 May 2025 | 140.85 | 161.20 |
| 04 Aug 2025 | Quarterly Result Announcement | NA | 04 Aug 2025 | 151.65 | 149.45 |
| 12 Aug 2025 | Annual General Meeting | NA | 12 Aug 2025 | 157.15 | 142.35 |
| 10 Nov 2025 | Quarterly Result Announcement | NA | 10 Nov 2025 | 137.05 | 133.30 |
Announcements
Announcement under Regulation 30 (LODR)-Press Release / Media Release
13 hours ago
13 hours agoConsolidation Of R&D Laboratories And Facilities7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication8 days ago
8 days agoFinancial Results For The Quarter And Half-Year Ended September 30 202510 days ago
10 days agoBoard Meeting Outcome for Outcome Of The Board Meeting For Approval Of Unaudited Financial Results For The Quarter And Half Yearly Ended September 30 202510 days ago
10 days agoBoard Meeting Intimation for Approval Of Unaudited Financial Results For Quarter And Half Year Ended September 30 2025Oct 31, 2025
Oct 31, 2025Clarification Regarding Increase In The VolumeOct 29, 2025
Oct 29, 2025Clarification sought from Sun Pharma Advanced Research Company LtdOct 29, 2025
Oct 29, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 09, 2025
Oct 09, 2025Closure of Trading WindowSep 26, 2025
Sep 26, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 05, 2025
Aug 05, 2025Unaudited Financial Results For The Quarter Ended June 30 2025Aug 04, 2025
Aug 04, 2025Board Meeting Outcome for Outcome Of The Board MeetingAug 04, 2025
Aug 04, 2025Board Meeting Intimation for Approval Of Unaudited Financial Statements For Quarter Ended June 30 2025Jul 28, 2025
Jul 28, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 24, 2025
Jul 24, 2025Reg. 34 (1) Annual Report.Jul 22, 2025
Jul 22, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 19, 2025
Jul 19, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 18, 2025
Jul 18, 2025Reg. 34 (1) Annual Report.Jul 18, 2025
Jul 18, 2025Notice Of 20Th Annual General Meeting Of Sun Pharma Advanced Research Company LtdJul 18, 2025
Jul 18, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 14, 2025
Jul 14, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 10, 2025
Jul 10, 2025Intimation Regarding 20Th Annual General Meeting Of The CompanyJul 08, 2025
Jul 08, 2025Regarding Incorporation Of Wholly Owned Subsidiary CompanyJul 05, 2025
Jul 05, 2025Closure of Trading WindowJun 26, 2025
Jun 26, 2025Update On Vibozilimod (SCD-044)Jun 03, 2025
Jun 03, 2025Clarification On Price MovementMay 29, 2025
May 29, 2025Clarification sought from Sun Pharma Advanced Research Company LtdMay 29, 2025
May 29, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 28, 2025
May 28, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 21, 2025
May 21, 2025Integrated Filing (Financial)May 19, 2025
May 19, 2025Appointment Of Secretarial AuditorMay 19, 2025
May 19, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateMay 19, 2025
May 19, 2025Audited Financial Results For The Quarter And Financial Year Ended March 31 2025May 19, 2025
May 19, 2025Board Meeting Outcome for Outcome Of The Board Meeting For Audited Financial Results Of The Company For The Quarter And Financial Year Ended March 31 2025May 19, 2025
May 19, 2025Board Meeting Intimation for Approval Of Audited Financial Results For The Year Ended March 31 2025 And Connected Matters.May 12, 2025
May 12, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 09, 2025
Apr 09, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 31, 2025
Mar 31, 2025Closure of Trading WindowMar 27, 2025
Mar 27, 2025Clarification On Price MovementMar 25, 2025
Mar 25, 2025Clarification sought from Sun Pharma Advanced Research Company LtdMar 25, 2025
Mar 25, 2025Announcement under Regulation 30 (LODR)-Credit RatingMar 05, 2025
Mar 05, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 12, 2025
Feb 12, 2025Integrated Filing (Financial)Feb 10, 2025
Feb 10, 2025Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E. February 10 2025Feb 10, 2025
Feb 10, 2025Financial Results For The Quarter And Nine Months Ended December 31 2024Feb 10, 2025
Feb 10, 2025Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024Jan 31, 2025
Jan 31, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJan 17, 2025
Jan 17, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 10, 2025
Jan 10, 2025Mutual Fund Holdings
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth 
Motilal Oswal Nifty Microcap 250 Index Fund Direct - Growth 
Groww Nifty Total Market Index Fund Direct - Growth 
Bandhan Nifty Total Market Index Fund Direct-Growth 
Angel One Nifty Total Market Index Fund Direct - Growth 
Mirae Asset Nifty Total Market Index Fund Direct-Growth 
HDFC Nifty Smallcap 250 Index Fund Direct-Growth 
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth 
Kotak Nifty Smallcap 250 Index Fund Direct-Growth 
Axis Nifty 500 Index Fund Direct-Growth 
Navi Nifty 500 Multicap 50:25:25 Index Fund Direct-Growth 
Nippon India Nifty 500 Equal Weight Index Fund Direct-Growth 
SBI Nifty 500 Index Fund Direct-Growth Technical Indicators
RSI(14)
Neutral 44.03
ATR(14)
Less Volatile 3.62
STOCH(9,6)
Neutral 25.85
STOCH RSI(14)
Oversold 5.11
MACD(12,26)
Bearish -0.32
ADX(14)
Weak Trend 16.58
UO(9)
Bearish 51.77
ROC(12)
Downtrend And Accelerating -3.31
WillR(14)
Oversold -81.07
About Sun Pharma Advanced Research Co
Sun Pharma Advanced Research Company Ltd. (SPARC) is an India-based clinical-stage biopharmaceutical company focused on developing new drugs and delivery systems. It specializes in creating therapeutics in oncology, neurology, and immunology. SPARC's key projects include vodobatinib for chronic myelogenous leukemia and neurodegenerative diseases, an anti-MUC-1 antibody-drug conjugate for multiple cancers, vibozilimod for autoimmune disorders, and SCD-153 for alopecia areata. The company engages in licensing agreements and partnerships for commercialization of its products. SPARC has received FDA approvals for some of its drugs, including XELPROS for glaucoma treatment. The company was incorporated in 2006 and operates independently after demerging from Sun Pharmaceutical Industries Ltd.
Website
Chairperson NameDilip S Shanghvi
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
